A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation

Authors

  • G G Van den Eynden,

    1. Translational Cancer Research Group (Laboratory Pathology University of Antwerp/University Hospital Antwerp and Oncology Centre, General Hospital St.-Augustinus, Wilrijk), Antwerp, Belgium, 1Surgical Pathology Section, Clinical Laboratory Division, National Cancer Centre Hospital East, Chiba and Office for Pathology Consultation Service, Clinical Trials and Practice Support Division, Centre for Cancer Control and Information Services, National Cancer Centre, Tokyo, Japan, 2Department of Pathology, Beaujon Hospital, APHP-University of Paris 7, Clichy Cedex, France and 3Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Search for more papers by this author
  • C G Colpaert,

    1. Translational Cancer Research Group (Laboratory Pathology University of Antwerp/University Hospital Antwerp and Oncology Centre, General Hospital St.-Augustinus, Wilrijk), Antwerp, Belgium, 1Surgical Pathology Section, Clinical Laboratory Division, National Cancer Centre Hospital East, Chiba and Office for Pathology Consultation Service, Clinical Trials and Practice Support Division, Centre for Cancer Control and Information Services, National Cancer Centre, Tokyo, Japan, 2Department of Pathology, Beaujon Hospital, APHP-University of Paris 7, Clichy Cedex, France and 3Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Search for more papers by this author
  • A Couvelard,

    1. Translational Cancer Research Group (Laboratory Pathology University of Antwerp/University Hospital Antwerp and Oncology Centre, General Hospital St.-Augustinus, Wilrijk), Antwerp, Belgium, 1Surgical Pathology Section, Clinical Laboratory Division, National Cancer Centre Hospital East, Chiba and Office for Pathology Consultation Service, Clinical Trials and Practice Support Division, Centre for Cancer Control and Information Services, National Cancer Centre, Tokyo, Japan, 2Department of Pathology, Beaujon Hospital, APHP-University of Paris 7, Clichy Cedex, France and 3Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Search for more papers by this author
  • 2 F Pezzella,

    1. Translational Cancer Research Group (Laboratory Pathology University of Antwerp/University Hospital Antwerp and Oncology Centre, General Hospital St.-Augustinus, Wilrijk), Antwerp, Belgium, 1Surgical Pathology Section, Clinical Laboratory Division, National Cancer Centre Hospital East, Chiba and Office for Pathology Consultation Service, Clinical Trials and Practice Support Division, Centre for Cancer Control and Information Services, National Cancer Centre, Tokyo, Japan, 2Department of Pathology, Beaujon Hospital, APHP-University of Paris 7, Clichy Cedex, France and 3Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Search for more papers by this author
  • 3 L Y Dirix,

    1. Translational Cancer Research Group (Laboratory Pathology University of Antwerp/University Hospital Antwerp and Oncology Centre, General Hospital St.-Augustinus, Wilrijk), Antwerp, Belgium, 1Surgical Pathology Section, Clinical Laboratory Division, National Cancer Centre Hospital East, Chiba and Office for Pathology Consultation Service, Clinical Trials and Practice Support Division, Centre for Cancer Control and Information Services, National Cancer Centre, Tokyo, Japan, 2Department of Pathology, Beaujon Hospital, APHP-University of Paris 7, Clichy Cedex, France and 3Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Search for more papers by this author
  • P B Vermeulen,

    1. Translational Cancer Research Group (Laboratory Pathology University of Antwerp/University Hospital Antwerp and Oncology Centre, General Hospital St.-Augustinus, Wilrijk), Antwerp, Belgium, 1Surgical Pathology Section, Clinical Laboratory Division, National Cancer Centre Hospital East, Chiba and Office for Pathology Consultation Service, Clinical Trials and Practice Support Division, Centre for Cancer Control and Information Services, National Cancer Centre, Tokyo, Japan, 2Department of Pathology, Beaujon Hospital, APHP-University of Paris 7, Clichy Cedex, France and 3Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Search for more papers by this author
  • E A Van Marck,

    1. Translational Cancer Research Group (Laboratory Pathology University of Antwerp/University Hospital Antwerp and Oncology Centre, General Hospital St.-Augustinus, Wilrijk), Antwerp, Belgium, 1Surgical Pathology Section, Clinical Laboratory Division, National Cancer Centre Hospital East, Chiba and Office for Pathology Consultation Service, Clinical Trials and Practice Support Division, Centre for Cancer Control and Information Services, National Cancer Centre, Tokyo, Japan, 2Department of Pathology, Beaujon Hospital, APHP-University of Paris 7, Clichy Cedex, France and 3Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Search for more papers by this author
  • and 1 T Hasebe

    1. Translational Cancer Research Group (Laboratory Pathology University of Antwerp/University Hospital Antwerp and Oncology Centre, General Hospital St.-Augustinus, Wilrijk), Antwerp, Belgium, 1Surgical Pathology Section, Clinical Laboratory Division, National Cancer Centre Hospital East, Chiba and Office for Pathology Consultation Service, Clinical Trials and Practice Support Division, Centre for Cancer Control and Information Services, National Cancer Centre, Tokyo, Japan, 2Department of Pathology, Beaujon Hospital, APHP-University of Paris 7, Clichy Cedex, France and 3Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Search for more papers by this author

Gert Van den Eynden, MD, Wetenschappelijk Laboratorium-Oncologisch Centrum, AZ St Augustinus, Oosterveldlaan 24, B2610 Wilrijk, Belgium. e-mail: gert.van.den.eynden@gza.be

Abstract

A fibrotic focus is a scar-like area in the centre of a carcinoma and can be regarded as a focus of exaggerated reactive tumour stroma formation. Although modern surgical pathology uses different histopathological and molecular markers to assess the aggressiveness and predict the behaviour of malignant tumours, markers reflecting stromal cell behaviour and interactions between epithelial cells and stromal cells are scarce. In this review we summarize all studies investigating the value of a fibrotic focus as a prognostic factor and as a surrogate marker for hypoxia and (lymph)angiogenesis in patients with breast cancer. These data show that a fibrotic focus can be used as a practical, easily assessable and reproducible integrative histological prognostic parameter in breast cancer. We propose a consensus methodology to assess the fibrotic focus in breast cancer.

Ancillary